Download
12016_2024_Article_9006.pdf 820,19KB
WeightNameValue
1000 Titel
  • Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review
1000 Autor/in
  1. Longhurst, Hilary J. |
  2. Cancian, Mauro |
  3. Grivcheva-Panovska, Vesna |
  4. Koleilat, Majed |
  5. Magerl, Markus |
  6. Savic, Sinisa |
  7. Stobiecki, Marcin |
  8. Tachdjian, Raffi |
  9. Healy, Bridget |
  10. Yea, Christopher M. |
  11. Audhya, Paul K. |
  12. Bouillet, Laurence |
1000 Verlag
  • Springer US
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-11-07
1000 Erschienen in
1000 Quellenangabe
  • 67(1):83-95
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12016-024-09006-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638394/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Long-term prophylaxis (LTP) has been shown to reduce the frequency of hereditary angioedema (HAE) attacks; however, attacks occurring in patients receiving LTP have not been well characterized. The objective of this systematic review was to evaluate the proportion of type I/II HAE (HAE-C1INH) patients who experience attacks while receiving LTP, the characteristics of these attacks, and associated on-demand therapy use. A systematic search was conducted in PubMed to identify studies reporting LTP use with plasma-derived C1 inhibitor (pdC1INH), lanadelumab, berotralstat, androgens, or antifibrinolytics in patients with HAE-C1INH. Forty-five primary studies met the inclusion criteria. In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60 IU/kg twice weekly at 16 weeks, and 44% for lanadelumab 300 mg every second week at 6 months (77% during steady-state [days 70–182]); there was no difference in attack-free rate for berotralstat 150 mg versus placebo at 24 weeks. Phase 3 studies reported a lower average attack severity with subcutaneous and intravenous pdC1INH versus placebo. With lanadelumab and berotralstat, the prophylactic treatment effect was more pronounced in peripheral attacks than in abdominal and laryngeal attacks. Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received. On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP. In conclusion, patients receiving LTP experienced attacks in all anatomic locations, including the larynx. Most attacks were treated with on-demand therapy, although outcomes were not reported. Access to on-demand therapy remains essential for all people with HAE-C1INH.</jats:p>
1000 Sacherschließung
lokal On-demand therapy
lokal Angioedemas, Hereditary/diagnosis [MeSH]
lokal Humans [MeSH]
lokal Systematic review
lokal Treatment Outcome [MeSH]
lokal Attack-free rate
lokal Clinical Trials, Phase III as Topic [MeSH]
lokal Hereditary angioedema
lokal Antibodies, Monoclonal, Humanized/therapeutic use [MeSH]
lokal Complement C1 Inhibitor Protein/therapeutic use [MeSH]
lokal Angioedemas, Hereditary/prevention
lokal Review
lokal Long-term prophylaxis
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TG9uZ2h1cnN0LCBIaWxhcnkgSi4=|https://frl.publisso.de/adhoc/uri/Q2FuY2lhbiwgTWF1cm8=|https://frl.publisso.de/adhoc/uri/R3JpdmNoZXZhLVBhbm92c2thLCBWZXNuYQ==|https://frl.publisso.de/adhoc/uri/S29sZWlsYXQsIE1hamVk|https://frl.publisso.de/adhoc/uri/TWFnZXJsLCBNYXJrdXM=|https://frl.publisso.de/adhoc/uri/U2F2aWMsIFNpbmlzYQ==|https://frl.publisso.de/adhoc/uri/U3RvYmllY2tpLCBNYXJjaW4=|https://frl.publisso.de/adhoc/uri/VGFjaGRqaWFuLCBSYWZmaQ==|https://frl.publisso.de/adhoc/uri/SGVhbHksIEJyaWRnZXQ=|https://frl.publisso.de/adhoc/uri/WWVhLCBDaHJpc3RvcGhlciBNLg==|https://frl.publisso.de/adhoc/uri/QXVkaHlhLCBQYXVsIEsu|https://frl.publisso.de/adhoc/uri/Qm91aWxsZXQsIExhdXJlbmNl
1000 Hinweis
  • DeepGreen-ID: b0dab859572a47688451b36cd1654cba ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. KalVista Pharmaceuticals |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer KalVista Pharmaceuticals |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6523476.rdf
1000 Erstellt am 2025-07-06T21:50:56.577+0200
1000 Erstellt von 322
1000 beschreibt frl:6523476
1000 Zuletzt bearbeitet 2025-07-29T20:08:39.223+0200
1000 Objekt bearb. Tue Jul 29 20:08:39 CEST 2025
1000 Vgl. frl:6523476
1000 Oai Id
  1. oai:frl.publisso.de:frl:6523476 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source